Literature DB >> 22753736

SIVmac₂₃₉-Nef down-regulates cell surface expression of CXCR4 in tumor cells and inhibits proliferation, migration and angiogenesis.

Chengzhong Cai1, Fiona R Rodepeter, Annette Rossmann, Afshin Teymoortash, Jin-Seok Lee, Karl Quint, Pietro DI Fazio, Matthias Ocker, Jochen A Werner, Robert Mandic.   

Abstract

AIM: To evaluate if the lentiviral accessory protein Nef can down-regulate the C-X-C chemokine receptor type 4 (CXCR4) in tumor cells and affect tumor cell proliferation, migration and angiogenesis.
MATERIALS AND METHODS: HeLa-(ACC) cells, which according to genotype analysis are virtually identical to the cervical cancer-derived HeLa cell line, were transfected with Nef from SIV(mac239) and expression levels of cell surface CXCR4 were monitored by flow cytometry. Real-time proliferation and migration of cells was measured with the xCELLigence system or with the in vitro scratch assay. In vitro tube formation was deployed to assess the effect of Nef on angiogenesis.
RESULTS: Cell surface down-regulation of CXCR4 was observed in HeLa-(ACC) cells after Nef transfection, as well as in the monkey kidney-derived COS-7 cell line after co-transfection of CXCR4 and Nef. Proliferation, as well as migration, of Nef-transfected HeLa-(ACC) cells appeared to be significantly reduced. In vitro tube formation was markedly lowered after Nef transfection, and CXCR4 knockdown with siRNA.
CONCLUSION: SIV-Nef could serve as an interesting tool to study the biological behavior of CXCR4-expressing tumor cells and could be helpful in the discovery of new therapeutic approaches for the treatment of CXCR4-positive tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22753736

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.

Authors:  Venkat R Katkoori; Marc D Basson; Vincent C Bond; Upender Manne; Harvey L Bumpers
Journal:  Oncotarget       Date:  2015-09-29

2.  The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism.

Authors:  Qing-Ling Yang; Ling-Yu Zhang; Hai-Feng Wang; Yu Li; Yue-Yue Wang; Tian-Tian Chen; Meng-Fen Dai; Hai-Hua Wu; Su-Lian Chen; Wen-Rui Wang; Qiong Wu; Chang-Jie Chen; Cong-Zhao Zhou
Journal:  Oncotarget       Date:  2017-06-06

Review 3.  Angiogenesis-related non-coding RNAs and gastrointestinal cancer.

Authors:  Zahra Sadat Razavi; Kasra Asgarpour; Maryam Mahjoubin-Tehran; Susan Rasouli; Haroon Khan; Mohammad Karim Shahrzad; Michael R Hamblin; Hamed Mirzaei
Journal:  Mol Ther Oncolytics       Date:  2021-05-15       Impact factor: 7.200

4.  Synergistic Chromatin-Modifying Treatments Reactivate Latent HIV and Decrease Migration of Multiple Host-Cell Types.

Authors:  Alexandra Blanco; Tarun Mahajan; Robert A Coronado; Kelly Ma; Dominic R Demma; Roy D Dar
Journal:  Viruses       Date:  2021-06-08       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.